A Phase 2 interventional study of CD14152 Dose A and CD14152 placebo in Prurigo Nodularis, sponsored by Galderma R&D. Completed at 16 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-19.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Prurigo with a site in Germany — 2 open to participants now, 7 under way, 3 of them phase 3. Prurigo · Germany.
Among the 20 studies in Prurigo with a site in Germany, this one is the 12th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2017, is one of 6 in phase 2, and was the 4th registered.
38 studies on the registry are indexed under Prurigo; 10 are open to participants now.
Browse Prurigo studies →2 of the 20 studies in Prurigo with a site in Germany are open now. Recruiting first, the newest first:
Beijing InnoCare Pharma Tech Co., Ltd. · Sites in Germany, United States, China and 2 more countries
Ages 18–75
Galderma R&D · Sites in Germany, United States
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 7 Prurigo studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 11
First in 2007; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is below the median of 135 across 31 interventional studies indexed under Prurigo.
Median enrollment 143 across the 18 interventional studies, 355 across the 2 observational. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 20 have an industry lead sponsor. The 9 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
Galderma Group AG has 6 studies filed under Prurigo — fewer than ten, so there is no comparison to draw.
2 of the studies in Prurigo with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07236099Beijing InnoCare Pharma Tech Co., Ltd.Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis | 2027-03 |
| NCT06988618Galderma R&DReal-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults | 2027-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Prurigo with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to assess the safety and efficacy of nemolizumab in subjects with prurigo nodularis.
This is a randomized, placebo-controlled, double-blinded, parallel group, multicenter study to evaluate the safety and efficacy of nemolizumab over a 12-week treatment period in patients suffering from prurigo nodularis compared to its placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical diagnosis of PN for at least 6 months with:
Severe pruritus defined as follows on a Numerical Rating Scale (NRS)
Female subjects must fulfill one of the criteria below:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 3 subcutaneous injections of placebo (matched to nemolizumab) every 4 weeks (Q4W) up to Week 8.
Drug: CD14152 placebo
Participants received 3 subcutaneous injections of nemolizumab 0.5 milligram per kilogram (mg/kg) Q4W up to Week 8.
Drug: CD14152 Dose A
3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
Also known as: Nemolizumab
3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
Also known as: Placebo
Percent Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale (NRS) Score at Week 4 Using Last Observation Carried Forward (LOCF) Approach
Pruritus NRS is a scale used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. Participants completed the assessment once daily at home in the evening. Participants were asked the following questions in their local language: 1) For average itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch overall during the previous 24 hours?"; 2) For maximum itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Where, higher score indicated worst imaginable itch. Missing values including those who took rescue medication were replaced by LOCF approach.
Time frame: Baseline, Week 4
Percent Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score at Week 4 Using Multiple Imputation (MI) Method
Pruritus NRS is a scale used by the participants to report the intensity of their pruritus (itch) during the last 24. Participants completed the assessment once daily at home in the evening. Participants were asked the following questions in their local language: 1) For average itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch overall during the previous 24 hours?"; 2) For maximum itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Where, higher score indicated worst imaginable itch. Multiple imputation generated twenty-five sets of data with missing values imputed from observed data using linear regression.
Time frame: Baseline, Week 4
Percent Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score at Week 4 Using Observed Data
Pruritus NRS is a scale used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. Participants completed the assessment once daily at home in the evening. Participants were asked the following questions in their local language: 1) For average itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch overall during the previous 24 hours?"; 2) For maximum itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Where, higher score indicated worst imaginable itch.
Time frame: Baseline, Week 4
Percent Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach
Pruritus NRS is a scale used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. Participants completed the assessment once daily at home in the evening. Participants were asked the following questions in their local language: 1) For average itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch overall during the previous 24 hours?"; 2) For maximum itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Where, higher score indicated worst imaginable itch. Missing values including those who took rescue medication were replaced by LOCF approach.
Time frame: Baseline, Weeks 1, 2, 4, 8, 12, 16 and 18
Absolute Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach
Pruritus NRS is a scale used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. Participants completed the assessment once daily at home in the evening. Participants were asked the following questions in their local language: 1) For average itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch overall during the previous 24 hours?"; 2) For maximum itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Where, higher score indicated worst imaginable itch. Missing values including those who took rescue medication were replaced by LOCF approach.
Time frame: Baseline, Weeks 1, 2, 4, 8, 12, 16 and 18
Percent Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach
Pruritus NRS is a scale used by the participants to report the intensity of their pruritus (itch) during the last 24. Participants completed the assessment once daily at home in the evening. Participants were asked the following questions in their local language: 1) For average itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch overall during the previous 24 hours?"; 2) For maximum itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Where, higher score indicated worst imaginable itch. Missing values including those who took rescue medication were replaced by LOCF approach.
Time frame: Baseline, Weeks 1, 2, 4, 8, 12, 16 and 18
Absolute Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach
Pruritus NRS is a scale used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. Participants completed the assessment once daily at home in the evening. Participants were asked the following questions in their local language: 1) For average itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch overall during the previous 24 hours?"; 2) For maximum itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Where, higher score indicated worst imaginable itch. Missing values including those who took rescue medication were replaced by LOCF approach.
Time frame: Baseline, Weeks 1, 2, 4, 8, 12, 16 and 18
Percent Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale (VRS) Score at Each Visit Using LOCF Approach
VRS consists of a list of adjectives describing different levels of symptom intensity used by participants to report intensity of their pruritus (itch) over last 24 hours. Participants marked on a 5-point VRS (0=no itch, 1=mild itch, 2=moderate itch, 3=severe itch, 4=very severe itch), a response that best described their pruritus intensity in last 24 hours. Participants were asked following questions in their local language: 1) For average itch intensity: "on a scale of 0-4, with 0 being 'no itch' and 4 being 'very severe itch', how would you rate your itch overall during previous 24 hours?"; 2) For maximum itch intensity: "on a scale of 0-4, with 0 being 'no itch' and 4 being 'very severe itch', how would you rate your worst itch during previous 24 hours?". Where, higher score indicated very severe itch. Missing values including those who took rescue medication were replaced by LOCF approach.
Time frame: Baseline, Weeks 1, 2, 4, 8, 12, 16 and 18
Absolute Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach
VRS consists of a list of adjectives describing different levels of symptom intensity used by participants to report intensity of their pruritus (itch) over last 24 hours. Participants marked on a 5-point VRS (0=no itch, 1=mild itch, 2=moderate itch, 3=severe itch, 4=very severe itch), a response that best described their pruritus intensity in last 24 hours. Participants were asked following questions in their local language: 1) For average itch intensity: "on a scale of 0-4, with 0 being 'no itch' and 4 being 'very severe itch', how would you rate your itch overall during previous 24 hours?"; 2) For maximum itch intensity: "on a scale of 0-4, with 0 being 'no itch' and 4 being 'very severe itch', how would you rate your worst itch during previous 24 hours?". Where, higher score indicated very severe itch. Missing values including those who took rescue medication were replaced by LOCF approach.
Time frame: Baseline, Weeks 1, 2, 4, 8, 12,16 and 18
Percent Change From Baseline in Weekly Average of the Average Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach
VRS consists of a list of adjectives describing different levels of symptom intensity used by participants to report intensity of their pruritus (itch) over last 24 hours. Participants marked on a 5-point VRS (0=no itch, 1=mild itch, 2=moderate itch, 3=severe itch, 4=very severe itch), a response that best described their pruritus intensity in last 24 hours. Participants were asked following questions in their local language: 1) For average itch intensity: "on a scale of 0-4, with 0 being 'no itch' and 4 being 'very severe itch', how would you rate your itch overall during previous 24 hours?"; 2) For maximum itch intensity: "on a scale of 0-4, with 0 being 'no itch' and 4 being 'very severe itch', how would you rate your worst itch during previous 24 hours?". Where, higher score indicated very severe itch. Missing values including those who took rescue medication were replaced by LOCF approach.
Time frame: Baseline, Weeks 1, 2, 4, 8, 12, 16 and 18
Absolute Change From Baseline in Weekly Average of the Average Verbal Rating Scale Score at Each Visit Using LOCF Approach
VRS consists of a list of adjectives describing different levels of symptom intensity used by participants to report intensity of their pruritus (itch) over last 24 hours. Participants marked on a 5-point VRS (0=no itch, 1=mild itch, 2=moderate itch, 3=severe itch, 4=very severe itch), a response that best described their pruritus intensity in last 24 hours. Participants were asked following questions in their local language: 1) For average itch intensity: "on a scale of 0-4, with 0 being 'no itch' and 4 being 'very severe itch', how would you rate your itch overall during previous 24 hours?"; 2) For maximum itch intensity: "on a scale of 0-4, with 0 being 'no itch' and 4 being 'very severe itch', how would you rate your worst itch during previous 24 hours?". Where, higher score indicated very severe itch. Missing values including those who took rescue medication were replaced by LOCF approach.
Time frame: Baseline, Weeks 1, 2, 4, 8, 12,16 and 18
Dynamic Pruritus Score (DPS) at 24, 48, and 72 Hours After First Injection and Before Second Injection (Week 4)
The 9-point DPS is a dynamic scale used by participants to evaluate the change of their pruritus compared with an earlier time point. The scale ranges from 0 (strongly worsened pruritus) to 8 (\[almost\] no pruritus anymore), including intermediate marks for slightly improved/worsened, moderately improved/worsened, and rather improved/worsened. Participants recorded their DPS score in their local language, and completed the assessment 24, 48 and 72 hours after the first injection at baseline and at week 4 before the second injection.
Time frame: After 24, 48, 72 hours of first Injection and before second injection (Week 4)
Prurigo Activity Score (PAS) Item 5: Overall Number of Prurigo Lesions at Week 12
PAS includes 7-descriptive items; 1) lesions type (papules nodules/plaques/umbilicated ulcers/ulcers/hypo-/hyperpigmented maculae); 2) number (prurigo lesions on whole body); 3) distribution (disseminated/localized \[only 1/2 areas affected\]/neither of them); 4) affected areas (forearm/upper arm/lower and upper leg/trunk/head); 5) number of prurigo lesions in selected area; 6) activity (prurigo lesions with excoriations/crusts and healed prurigo lesions compared to all prurigo lesions) and 7) front and back, areas of marked monitor lesions to recognize on next visit.
Time frame: Baseline, Week 12
Prurigo Activity Score (PAS) Item 6: Number of Participants With Defined Stages of Excoriation/Crusts and Healed Lesions at Each Visit
PAS includes 7-descriptive items; 1) lesions type (papules nodules/plaques/umbilicated ulcers/ulcers/hypo-/hyperpigmented maculae); 2) number (prurigo lesions on whole body); 3) distribution (disseminated/localized \[only 1/2 areas affected\]/neither of them); 4) affected areas (forearm/upper arm/lower and upper leg/trunk/head); 5) number of prurigo lesions in selected area; 6) activity (prurigo lesions with excoriations/crusts and healed prurigo lesions compared to all prurigo lesions) and 7) front and back, areas of marked monitor lesions to recognize on next visit. Item 6 has 5 stages (0-4) where each stage represents percentage of prurigo lesions with excoriations/crusts and healed prurigo lesions compared to all prurigo lesions: excoriations/crusts lesions; stage 0=0%, 1=1-25%, 2=26-50%, 3=51-75%, 4=76-100%; for healed lesions; stage 0=100%, 1=75-99%, 2=50-74%, 3=25-49%, 4=0-24%.
Time frame: Day 1 (Baseline), Weeks 4, 8, 12 and 18
Investigator Global Assessment (IGA) Score at Each Visit
IGA is a 5-point scale used by the investigator or trained designee to evaluate the severity of the disease ranging from 0 to 4 where, 0 = clear, 1= almost clear, 2 = mild, 3 = moderate and 4 severe. IGA corresponds to the overall assessment of the severity of prurigo including presence of crust and nodules or skin bleeding. Higher score indicated greater severity of disease.
Time frame: Day 1 (Baseline), Weeks 4, 8, 12 and 18
Percentage of Participants Achieving Investigator Global Assessment Success (Defined as IGA= 0 [Clear] or IGA = 1 [Almost Clear] With Two-point Improvement From Baseline) at Week 12
IGA is a 5-point scale used by the investigator or trained designee to evaluate the severity of the disease ranging from 0 to 4 where, 0 = clear, 1= almost clear, 2 = mild, 3 = moderate and 4 severe. IGA corresponds to the overall assessment of the severity of prurigo including presence of crust and nodules or skin bleeding. Higher score indicated greater severity of disease.
Time frame: Week 12
The study was conducted at 16 sites in 4 countries.
| Milestone | Placebo | Nemolizumab 0.5 mg/kg |
|---|---|---|
| Started | 36 | 34 |
| Treated | 36 | 34 |
| Completed | 29 | 31 |
| Not completed | 7 | 3 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 |
Pruritus NRS is a scale used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. Participants completed the assessment once daily at home in the evening. Participants were asked the following questions in their local language: 1) For average itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch overall during the previous 24 hours?"; 2) For maximum itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Where, higher score indicated worst imaginable itch. Missing values including those who took rescue medication were replaced by LOCF approach.
| Percent change | Placebo | Nemolizumab 0.5 mg/kg |
|---|---|---|
| Percent Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale (NRS) Score at Week 4 Using Last Observation Carried Forward (LOCF) Approach | -13.8 ± 16.10 | -52.6 ± 33.96 |
Pruritus NRS is a scale used by the participants to report the intensity of their pruritus (itch) during the last 24. Participants completed the assessment once daily at home in the evening. Participants were asked the following questions in their local language: 1) For average itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch overall during the previous 24 hours?"; 2) For maximum itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Where, higher score indicated worst imaginable itch. Multiple imputation generated twenty-five sets of data with missing values imputed from observed data using linear regression.
| Percent change | Placebo | Nemolizumab 0.5 mg/kg |
|---|---|---|
| Percent Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score at Week 4 Using Multiple Imputation (MI) Method | -18.3 ± 22.39 | -52.0 ± 33.94 |
Pruritus NRS is a scale used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. Participants completed the assessment once daily at home in the evening. Participants were asked the following questions in their local language: 1) For average itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch overall during the previous 24 hours?"; 2) For maximum itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Where, higher score indicated worst imaginable itch. Missing values including those who took rescue medication were replaced by LOCF approach.
| percent change | Placebo | Nemolizumab 0.5 mg/kg |
|---|---|---|
| Week 1 | -6.1 ± 11.45 | -26.0 ± 21.93 |
| Week 2 | -7.4 ± 14.85 | -41.7 ± 30.31 |
| Week 4 | -13.8 ± 16.10 | -52.6 ± 33.96 |
| Week 8 | -19.7 ± 20.03 | -56.5 ± 34.73 |
| Week 12 | -18.7 ± 22.80 | -61.8 ± 34.95 |
| Week 16 | -20.8 ± 22.29 | -61.1 ± 35.35 |
| Week 18 | -21.7 ± 22.95 | -59.6 ± 35.89 |
Pruritus NRS is a scale used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. Participants completed the assessment once daily at home in the evening. Participants were asked the following questions in their local language: 1) For average itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch overall during the previous 24 hours?"; 2) For maximum itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Where, higher score indicated worst imaginable itch. Missing values including those who took rescue medication were replaced by LOCF approach.
| Units on a scale | Placebo | Nemolizumab 0.5 mg/kg |
|---|---|---|
| Week 1 | -0.5 ± 0.87 | -2.1 ± 1.66 |
| Week 2 | -0.6 ± 1.21 | -3.4 ± 2.38 |
| Week 4 | -1.2 ± 1.33 | -4.3 ± 2.77 |
| Week 8 | -1.6 ± 1.62 | -4.7 ± 2.90 |
| Week 12 | -1.5 ± 1.84 | -5.1 ± 2.95 |
| Week 16 | -1.7 ± 1.81 | -5.1 ± 3.00 |
| Week 18 | -1.8 ± 1.87 | -4.9 ± 3.07 |
Pruritus NRS is a scale used by the participants to report the intensity of their pruritus (itch) during the last 24. Participants completed the assessment once daily at home in the evening. Participants were asked the following questions in their local language: 1) For average itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch overall during the previous 24 hours?"; 2) For maximum itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Where, higher score indicated worst imaginable itch. Missing values including those who took rescue medication were replaced by LOCF approach.
| Percent change | Placebo | Nemolizumab 0.5 mg/kg |
|---|---|---|
| Week 1 | -7.5 ± 12.82 | -26.6 ± 21.25 |
| Week 2 | -9.6 ± 15.28 | -44.0 ± 29.54 |
| Week 4 | -16.5 ± 18.25 | -53.4 ± 33.23 |
| Week 8 | -24.6 ± 23.38 | -57.3 ± 34.78 |
| Week 12 | -23.0 ± 26.31 | -62.6 ± 34.98 |
| Week 16 | -25.9 ± 24.89 | -62.4 ± 35.93 |
| Week 18 | -26.2 ± 25.39 | -60.4 ± 36.15 |
Pruritus NRS is a scale used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. Participants completed the assessment once daily at home in the evening. Participants were asked the following questions in their local language: 1) For average itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch overall during the previous 24 hours?"; 2) For maximum itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Where, higher score indicated worst imaginable itch. Missing values including those who took rescue medication were replaced by LOCF approach.
| Units on a scale | Placebo | Nemolizumab 0.5 mg/kg |
|---|---|---|
| Week 1 | -0.5 ± 0.82 | -1.9 ± 1.47 |
| Week 2 | -0.8 ± 1.14 | -3.2 ± 2.03 |
| Week 4 | -1.3 ± 1.41 | -3.9 ± 2.44 |
| Week 8 | -1.9 ± 1.80 | -4.2 ± 2.60 |
| Week 12 | -1.8 ± 2.05 | -4.6 ± 2.71 |
| Week 16 | -2.0 ± 1.97 | -4.6 ± 2.86 |
| Week 18 | -2.1 ± 2.02 | -4.5 ± 2.94 |
VRS consists of a list of adjectives describing different levels of symptom intensity used by participants to report intensity of their pruritus (itch) over last 24 hours. Participants marked on a 5-point VRS (0=no itch, 1=mild itch, 2=moderate itch, 3=severe itch, 4=very severe itch), a response that best described their pruritus intensity in last 24 hours. Participants were asked following questions in their local language: 1) For average itch intensity: "on a scale of 0-4, with 0 being 'no itch' and 4 being 'very severe itch', how would you rate your itch overall during previous 24 hours?"; 2) For maximum itch intensity: "on a scale of 0-4, with 0 being 'no itch' and 4 being 'very severe itch', how would you rate your worst itch during previous 24 hours?". Where, higher score indicated very severe itch. Missing values including those who took rescue medication were replaced by LOCF approach.
| Percent change | Placebo | Nemolizumab 0.5 mg/kg |
|---|---|---|
| Week 1 | -9.8 ± 14.24 | -27.6 ± 17.21 |
| Week 2 | -12.3 ± 17.64 | -39.1 ± 25.38 |
| Week 4 | -15.6 ± 20.95 | -50.7 ± 29.37 |
| Week 8 | -20.7 ± 21.22 | -54.3 ± 30.61 |
| Week 12 | -19.4 ± 23.60 | -56.9 ± 32.64 |
| Week 16 | -21.2 ± 22.24 | -55.6 ± 34.48 |
| Week 18 | -23.0 ± 21.97 | -53.4 ± 36.56 |
VRS consists of a list of adjectives describing different levels of symptom intensity used by participants to report intensity of their pruritus (itch) over last 24 hours. Participants marked on a 5-point VRS (0=no itch, 1=mild itch, 2=moderate itch, 3=severe itch, 4=very severe itch), a response that best described their pruritus intensity in last 24 hours. Participants were asked following questions in their local language: 1) For average itch intensity: "on a scale of 0-4, with 0 being 'no itch' and 4 being 'very severe itch', how would you rate your itch overall during previous 24 hours?"; 2) For maximum itch intensity: "on a scale of 0-4, with 0 being 'no itch' and 4 being 'very severe itch', how would you rate your worst itch during previous 24 hours?". Where, higher score indicated very severe itch. Missing values including those who took rescue medication were replaced by LOCF approach.
| Units on a scale | Placebo | Nemolizumab 0.5 mg/kg |
|---|---|---|
| Week 1 | -0.3 ± 0.47 | -0.9 ± 0.57 |
| Week 2 | -0.4 ± 0.61 | -1.3 ± 0.83 |
| Week 4 | -0.6 ± 0.74 | -1.6 ± 1.00 |
| Week 8 | -0.7 ± 0.74 | -1.8 ± 1.06 |
| Week 12 | -0.7 ± 0.83 | -1.8 ± 1.09 |
| Week 16 | -0.7 ± 0.78 | -1.8 ± 1.16 |
| Week 18 | -0.8 ± 0.77 | -1.7 ± 1.26 |
VRS consists of a list of adjectives describing different levels of symptom intensity used by participants to report intensity of their pruritus (itch) over last 24 hours. Participants marked on a 5-point VRS (0=no itch, 1=mild itch, 2=moderate itch, 3=severe itch, 4=very severe itch), a response that best described their pruritus intensity in last 24 hours. Participants were asked following questions in their local language: 1) For average itch intensity: "on a scale of 0-4, with 0 being 'no itch' and 4 being 'very severe itch', how would you rate your itch overall during previous 24 hours?"; 2) For maximum itch intensity: "on a scale of 0-4, with 0 being 'no itch' and 4 being 'very severe itch', how would you rate your worst itch during previous 24 hours?". Where, higher score indicated very severe itch. Missing values including those who took rescue medication were replaced by LOCF approach.
| percent change | Placebo | Nemolizumab 0.5 mg/kg |
|---|---|---|
| Week 1 | -10.5 ± 19.72 | -29.6 ± 16.90 |
| Week 2 | -13.0 ± 19.20 | -42.9 ± 24.22 |
| Week 4 | -16.4 ± 24.10 | -52.1 ± 27.63 |
| Week 8 | -23.5 ± 22.89 | -55.4 ± 30.63 |
| Week 12 | -21.9 ± 25.90 | -62.1 ± 29.98 |
| Week 16 | -25.1 ± 24.15 | -62.0 ± 32.48 |
| Week 18 | -26.2 ± 24.40 | -58.7 ± 34.81 |
VRS consists of a list of adjectives describing different levels of symptom intensity used by participants to report intensity of their pruritus (itch) over last 24 hours. Participants marked on a 5-point VRS (0=no itch, 1=mild itch, 2=moderate itch, 3=severe itch, 4=very severe itch), a response that best described their pruritus intensity in last 24 hours. Participants were asked following questions in their local language: 1) For average itch intensity: "on a scale of 0-4, with 0 being 'no itch' and 4 being 'very severe itch', how would you rate your itch overall during previous 24 hours?"; 2) For maximum itch intensity: "on a scale of 0-4, with 0 being 'no itch' and 4 being 'very severe itch', how would you rate your worst itch during previous 24 hours?". Where, higher score indicated very severe itch. Missing values including those who took rescue medication were replaced by LOCF approach.
| Units on a scale | Placebo | Nemolizumab 0.5 mg/kg |
|---|---|---|
| Week 1 | -0.4 ± 0.50 | -0.9 ± 0.49 |
| Week 2 | -0.4 ± 0.61 | -1.3 ± 0.68 |
| Week 4 | -0.6 ± 0.73 | -1.6 ± 0.84 |
| Week 8 | -0.7 ± 0.72 | -1.7 ± 0.96 |
| Week 12 | -0.7 ± 0.82 | -1.9 ± 0.94 |
| Week 16 | -0.8 ± 0.78 | -1.9 ± 1.06 |
| Week 18 | -0.8 ± 0.79 | -1.8 ± 1.16 |
The 9-point DPS is a dynamic scale used by participants to evaluate the change of their pruritus compared with an earlier time point. The scale ranges from 0 (strongly worsened pruritus) to 8 (\[almost\] no pruritus anymore), including intermediate marks for slightly improved/worsened, moderately improved/worsened, and rather improved/worsened. Participants recorded their DPS score in their local language, and completed the assessment 24, 48 and 72 hours after the first injection at baseline and at week 4 before the second injection.
| Units on a scale | Placebo | Nemolizumab 0.5 mg/kg |
|---|---|---|
| First injection, after 24 hours | 4.3 ± 0.96 | 5.0 ± 1.20 |
| First injection, after 48 hours | 4.0 ± 1.69 | 5.3 ± 1.40 |
| First injection, after 72 hours | 4.0 ± 1.37 | 5.7 ± 1.34 |
| Before Second Injection (Week 4) | 4.4 ± 1.07 | 6.3 ± 1.89 |
PAS includes 7-descriptive items; 1) lesions type (papules nodules/plaques/umbilicated ulcers/ulcers/hypo-/hyperpigmented maculae); 2) number (prurigo lesions on whole body); 3) distribution (disseminated/localized \[only 1/2 areas affected\]/neither of them); 4) affected areas (forearm/upper arm/lower and upper leg/trunk/head); 5) number of prurigo lesions in selected area; 6) activity (prurigo lesions with excoriations/crusts and healed prurigo lesions compared to all prurigo lesions) and 7) front and back, areas of marked monitor lesions to recognize on next visit.
| Prurigo Lesions | Placebo | Nemolizumab 0.5 mg/kg |
|---|---|---|
| Baseline | 87.1 ± 5.42 | 84.9 ± 5.50 |
| Week 12 | 74.2 ± 6.83 | 54.8 ± 6.42 |
PAS includes 7-descriptive items; 1) lesions type (papules nodules/plaques/umbilicated ulcers/ulcers/hypo-/hyperpigmented maculae); 2) number (prurigo lesions on whole body); 3) distribution (disseminated/localized \[only 1/2 areas affected\]/neither of them); 4) affected areas (forearm/upper arm/lower and upper leg/trunk/head); 5) number of prurigo lesions in selected area; 6) activity (prurigo lesions with excoriations/crusts and healed prurigo lesions compared to all prurigo lesions) and 7) front and back, areas of marked monitor lesions to recognize on next visit. Item 6 has 5 stages (0-4) where each stage represents percentage of prurigo lesions with excoriations/crusts and healed prurigo lesions compared to all prurigo lesions: excoriations/crusts lesions; stage 0=0%, 1=1-25%, 2=26-50%, 3=51-75%, 4=76-100%; for healed lesions; stage 0=100%, 1=75-99%, 2=50-74%, 3=25-49%, 4=0-24%.
| Participants | Placebo | Nemolizumab 0.5 mg/kg |
|---|---|---|
| Excoriation/Crusts: Day 1: Stage 0 | 0 | 0 |
| Excoriation/Crusts: Day 1: Stage 1 | 2 | 4 |
| Excoriation/Crusts: Day 1: Stage 2 | 7 | 5 |
| Excoriation/Crusts: Day 1: Stage 3 | 14 | 12 |
| Excoriation/Crusts: Day 1: Stage 4 | 13 | 13 |
| Excoriation/Crusts: Week 4: Stage 0 | 2 | 2 |
| Excoriation/Crusts: Week 4: Stage 1 | 6 | 10 |
| Excoriation/Crusts: Week 4: Stage 2 | 7 | 9 |
| Excoriation/Crusts: Week 4: Stage 3 | 10 | 9 |
| Excoriation/Crusts: Week 4: Stage 4 | 9 | 3 |
| Excoriation/Crusts: Week 8: Stage 0 | 2 | 4 |
| Excoriation/Crusts: Week 8: Stage 1 | 5 | 13 |
| Excoriation/Crusts: Week 8: Stage 2 | 7 | 6 |
| Excoriation/Crusts: Week 8: Stage 3 | 11 | 9 |
| Excoriation/Crusts: Week 8: Stage 4 | 7 | 0 |
| Excoriation/CrustsWeek 12: Stage 0 | 1 | 3 |
| Excoriation/Crusts: Week 12: Stage 1 | 7 | 17 |
| Excoriation/Crusts: Week 12: Stage 2 | 5 | 9 |
| Excoriation/Crusts: Week 12: Stage 3 | 12 | 3 |
| Excoriation/Crusts: Week 12: Stage 4 | 5 | 0 |
| Excoriation/Crusts: Week 18: Stage 0 | 1 | 6 |
| Excoriation/Crusts: Week 18: Stage 1 | 4 | 12 |
| Excoriation/Crusts: Week 18: Stage 2 | 8 | 4 |
| Excoriation/Crusts: Week 18: Stage 3 | 11 | 5 |
| Excoriation/Crusts: Week 18: Stage 4 | 6 | 4 |
| Healed Lesions: Day 1: Stage 0 | 1 | 0 |
| Healed Lesions: Day 1: Stage 1 | 0 | 1 |
| Healed Lesions: Day 1: Stage 2 | 3 | 5 |
| Healed Lesions: Day 1: Stage 3 | 13 | 9 |
| Healed Lesions: Day 1: Stage 4 | 19 | 19 |
| Healed Lesions: Week 4: Stage 0 | 2 | 3 |
| Healed Lesions: Week 4: Stage 1 | 2 | 5 |
| Healed Lesions: Week 4: Stage 2 | 6 | 5 |
| Healed Lesions: Week 4: Stage 3 | 11 | 14 |
| Healed Lesions: Week 4: Stage 4 | 13 | 6 |
| Healed Lesions: Week 8: Stage 0 | 2 | 3 |
| Healed Lesions: Week 8: Stage 1 | 3 | 8 |
| Healed Lesions: Week 8: Stage 2 | 7 | 8 |
| Healed Lesions: Week 8: Stage 3 | 9 | 12 |
| Healed Lesions: Week 8: Stage 4 | 11 | 1 |
| Healed Lesions: Week 12: Stage 0 | 1 | 2 |
| Healed Lesions: Week 12: Stage 1 | 2 | 9 |
| Healed Lesions: Week 12: Stage 2 | 7 | 16 |
| Healed Lesions: Week 12: Stage 3 | 8 | 5 |
| Healed Lesions: Week 12: Stage 4 | 12 | 0 |
| Healed Lesions: Week 18: Stage 0 | 1 | 3 |
| Healed Lesions: Week 18: Stage 1 | 2 | 12 |
| Healed Lesions: Week 18: Stage 2 | 7 | 7 |
| Healed Lesions: Week 18: Stage 3 | 8 | 5 |
| Healed Lesions: Week 18: Stage 4 | 12 | 4 |
IGA is a 5-point scale used by the investigator or trained designee to evaluate the severity of the disease ranging from 0 to 4 where, 0 = clear, 1= almost clear, 2 = mild, 3 = moderate and 4 severe. IGA corresponds to the overall assessment of the severity of prurigo including presence of crust and nodules or skin bleeding. Higher score indicated greater severity of disease.
| Units on a scale | Placebo | Nemolizumab 0.5 mg/kg |
|---|---|---|
| Day 1 (Baseline) | 3.4 ± 0.49 | 3.5 ± 0.51 |
| Week 4 | 3.3 ± 0.61 | 2.8 ± 0.81 |
| Week 8 | 3.1 ± 0.67 | 2.4 ± 0.80 |
| Week 12 | 2.8 ± 0.82 | 2.0 ± 0.80 |
| Week 18 | 3.0 ± 0.93 | 2.0 ± 1.11 |
IGA is a 5-point scale used by the investigator or trained designee to evaluate the severity of the disease ranging from 0 to 4 where, 0 = clear, 1= almost clear, 2 = mild, 3 = moderate and 4 severe. IGA corresponds to the overall assessment of the severity of prurigo including presence of crust and nodules or skin bleeding. Higher score indicated greater severity of disease.
| percentage of participants | Placebo | Nemolizumab 0.5 mg/kg |
|---|---|---|
| Percentage of Participants Achieving Investigator Global Assessment Success (Defined as IGA= 0 [Clear] or IGA = 1 [Almost Clear] With Two-point Improvement From Baseline) at Week 12 | 2.8 | 20.6 |
Pruritus NRS is a scale used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. Participants completed the assessment once daily at home in the evening. Participants were asked the following questions in their local language: 1) For average itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch overall during the previous 24 hours?"; 2) For maximum itch intensity: "on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Where, higher score indicated worst imaginable itch.
| Percent change | Placebo | Nemolizumab 0.5 mg/kg |
|---|---|---|
| Percent Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score at Week 4 Using Observed Data | -15.2 ± 17.42 | -54.9 ± 33.80 |
Collected over Up to 18 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/36 (0%) | 3/36 (8.3%) | 22/36 (61.1%) |
| Nemolizumab 0.5 mg/kg | 0/34 (0%) | 4/34 (11.8%) | 26/34 (76.5%) |
| Event | Placebo | Nemolizumab 0.5 mg/kg |
|---|---|---|
| NeurodermatitisSkin and subcutaneous tissue disorders | 3/36 | 0/34 |
| Dermatitis PsoriasiformSkin and subcutaneous tissue disorders | 0/36 | 1/34 |
| Eczema NummularSkin and subcutaneous tissue disorders | 0/36 | 1/34 |
| Clavicle FractureInjury, poisoning and procedural complications | 0/36 | 1/34 |
| FibromyalgiaMusculoskeletal and connective tissue disorders | 0/36 | 1/34 |
| Calculus BladderRenal and urinary disorders | 0/36 | 1/34 |
| Spinal FractureInjury, poisoning and procedural complications | 1/36 | 0/34 |
| Back PainMusculoskeletal and connective tissue disorders | 1/36 | 0/34 |
| Event | Placebo | Nemolizumab 0.5 mg/kg |
|---|---|---|
| NasopharyngitisInfections and infestations | 4/36 | 5/34 |
| NeurodermatitisSkin and subcutaneous tissue disorders | 5/36 | 2/34 |
| ConjunctivitisInfections and infestations | 2/36 | 3/34 |
| Dermatitis AtopicSkin and subcutaneous tissue disorders | 0/36 | 3/34 |
| BronchitisInfections and infestations | 0/36 | 2/34 |
| Dermatitis ContactSkin and subcutaneous tissue disorders | 0/36 | 2/34 |
| Abdominal PainGastrointestinal disorders | 0/36 | 2/34 |
| DiarrhoeaGastrointestinal disorders | 0/36 | 2/34 |
| LymphadenopathyBlood and lymphatic system disorders | 0/36 | 2/34 |
| Increased AppetiteMetabolism and nutrition disorders | 0/36 | 2/34 |
Analysis was performed on all randomized participants.
| Age, Continuous(years) | Placebo | Nemolizumab 0.5 mg/kg | Total |
|---|---|---|---|
| Mean | 52.4 ± 17.47 | 59.7 ± 13.16 | 56.0 ± 15.85 |
| Sex: Female, Male(Participants) | Placebo | Nemolizumab 0.5 mg/kg | Total |
|---|---|---|---|
| Female | 22 | 19 | 41 |
| Male | 14 | 15 | 29 |
| Race (NIH/OMB)(Participants) | Placebo | Nemolizumab 0.5 mg/kg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 35 | 33 | 68 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Presence or absence of background of atopy(Participants) | Placebo | Nemolizumab 0.5 mg/kg | Total |
|---|---|---|---|
| Presence | 6 | 5 | 11 |
| Absence | 30 | 29 | 59 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2017 to primary completion in Sep 2018, 11 months.
Results were first posted in Feb 2020, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nemolizumab